At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

在一项大型后期试验中，阿斯利康和第一三共的重磅药物Enhertu作为初始治疗时，显著延长试验特定乳腺癌的生长。该试验结果有望助力Enhertu扩大适用范围，并十年来首次改变该疾病的治疗方式。

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Annual Meeting of the American Society of Clinical Oncology (ASCO), this year held in Chicago, Illinois from May 30 to June 2 ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.